Brief: Active Biotech Partner NeoTX Enters Clinical Collaboration With AstraZeneca

Active Biotech AB publ

11/02/2019 14:13

Feb 11 (Reuters) - Active Biotech Ab  ACTI.ST :
    * REG-ACTIVE BIOTECH'S PARTNER NEOTX ENTERS CLINICAL
COLLABORATION
WITH ASTRAZENECA TO EVALUATE ANYARA IN COMBINATION WITH IMFINZI®
(DURVALUMAB) IN THE UPCOMING PHASE 1B/2 STUDY
    * NEOTX WILL SPONSOR STUDY, WHILE ASTRAZENECA WILL SUPPLY
DURVALUMAB
    * UNDER TERMS OF AGREEMENT, NEOTX AND ASTRAZENECA WILL
COLLABORATE
ON A NON-EXCLUSIVE BASIS TO EVALUATE COMBINATION OF TWO DRUGS IN
SOLID TUMORS
    * NEOTX WILL SPONSOR STUDY, WHILE ASTRAZENECA WILL SUPPLY
DURVALUMAB

Source text for Eikon:  ID:nGNE953sGW 
Further company coverage:  ACTI.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))